Cisplatin and gemcitabine in malignant mesothelioma

We read with interest Steele and Klabatsa's review of chemotherapy in malignant mesothelioma [1Go]. Whilst we welcome the randomised evidence for a survival benefit from pemetrexed and cisplatin, we believe the activity of gemcitabine and cisplatin in this disease has been misrepresented. The authors correctly reported our single centre study of this combination, with a response rate of 48% (95% CI 26% to 69%) in 21 patients [2Go]. However, they have not reported that this study was followed with a multicentre phase II study of the same combination and schedule in 53 patients, giving a response rate of 33% (95% CI 20% to 46%) [3Go] and supporting the ability of this regimen to palliate some of the worst-rated symptoms of this disease [4Go]. These studies used a 28-day regimen with cisplatin 100 mg/m2 on day 1 and gemcitabine 1000 mg/m2 on days 1, 8 and 15. Trials showing lower response rates (16% and 26%) for this combination used 21-day schedules, with cisplatin doses of 75–80 mg/m2 [5Go, 6Go]. Furthermore, these trials used WHO response criteria in a disease in which bi-dimensional measurement of tumour response is probably inappropriate [7Go].

Unfortunately, whilst we would welcome a randomised comparison of cisplatin and pemetrexed versus cisplatin and gemcitabine in this disease, this is unlikely to occur as the same pharmaceutical company manufactures both pemetrexed and gemcitabine.

A. K. Nowak1,2,* and M. J. Byrne1

1 Department of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, WA, 6009 Australia; 2 Department of Medicine and Pharmacology, University of Western Australia, Nedlands, WA, 6009 Australia

* E-mail: anowak{at}cyllene.uwa.edu.au or Anna.Nowak{at}health.wa.gov.au

References

1. Steele JPC, Klabatsa A. Chemotherapy options and new advances in malignant pleural mesothelioma. Ann Oncol 2005; 16: 345–351.[Abstract/Free Full Text]

2. Byrne MJ, Davidson JA, Musk AW et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: A phase II study. J Clin Oncol 1999; 17: 25–30.[Free Full Text]

3. Nowak AK, Byrne MJ, Williamson R et al. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 2002; 87: 491–496.[CrossRef][ISI][Medline]

4. Nowak AK, Stockler MR, Byrne MJ. Assessing quality of life during chemotherapy for pleural mesothelioma: feasibility, validity, and results of using the European Organization for Research and Treatment of Cancer core quality of life questionnaire and lung cancer module. J Clin Oncol 2004; 22: 3172–3180.[Abstract/Free Full Text]

5. Van Haarst JMW, Baas P, Manegold C et al. Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer 2002; 86: 342–345.[CrossRef][ISI][Medline]

6. Castagneto B, Zai S, Dongiovanni V et al. Cisplatin and gemcitabine in malignant pleural mesothelioma: A phase II study. Proc Am Soc Clin Oncol 2003; 22: 656 (Abstr 2637).

7. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004; 15: 257–260.[Abstract/Free Full Text]





This Article
Full Text (PDF)
All Versions of this Article:
16/10/1711-a    most recent
mdi303v1
E-letters: Submit a response
Alert me when this article is cited
Alert me when E-letters are posted
Alert me if a correction is posted
Services
Email this article to a friend
Similar articles in this journal
Similar articles in PubMed
Alert me to new issues of the journal
Add to My Personal Archive
Download to citation manager
Disclaimer
Request Permissions
Google Scholar
Articles by Nowak, A. K.
Articles by Byrne, M. J.
PubMed
PubMed Citation
Articles by Nowak, A. K.
Articles by Byrne, M. J.